{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"6","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Assessed in the crossover arm using the method of Kaplan Meier. Progression is defined using the International Uniform Response Criteria for Multiple Myeloma as new or increase in size of existing bone lesions or soft tissue plasmacytomas; or development of hypercalcemia attributable solely to MM; or ≥ 25% increase from baseline or lowest response level of either serum M protein, urine M protein, difference in involved \\& uninvolved serum free light chain level or bone marrow plasma cell percentage.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m\\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Arm III (Crossover Group)"}],"paramType":"MEDIAN","populationDescription":"Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive high dose carfilzomib","reportingStatus":"POSTED","timeFrame":"From date of crossover to date of subsequent documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years from randomization","title":"Progression-free Survival of Crossover Group","type":"SECONDARY","unitOfMeasure":"months"}